• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA opens the doors for parallel review with Medicare

FDA opens the doors for parallel review with Medicare

October 7, 2011 By MassDevice staff

FDA

Medical device companies can opt to shave some time off their device clearance and Medicare reimbursement reviews by opting to have both applications considered simultaneously.

The FDA and the Centers for Medicare & Medicaid Services launched a "parallel review" pilot program for voluntary simultaneous review and med-tech companies wanting to give it a try can sign up beginning today.

"The pilot program will help the FDA and CMS streamline the parallel review process so that it works efficiently for expedient patient access to safe and effective medical devices," CDRH director Dr. Jeffrey Shuren said in a press release.

Both agencies use clinical data to make decisions and running simultaneous review may help cut down the overall time it takes for a product to reach the market.

"The parallel review program has the potential to increase patient access to innovative devices that improve clinical outcomes," CMS chief medical officer Dr. Patrick Conway said in the release. "Our goal is to reduce regulatory burden and improve patient outcomes."

The two agencies first began sharing data in July 2010 with the singing of a Memorandum of Understanding.

The MOU, Shuren said at the time, "will allow for the first time routine and timely sharing of information and expertise between our two agencies to strengthen our ability to achieve our respective missions." 

Industry news sources saw greater potential, however, characterizing the agreement as "a first step toward parallel reviews for marketing approval and Medicare coverage."

That prediction came to pass just months later when the FDA and CMS announced plans to team up on medical devices in September 2010.

While the program was met with some enthusiasm, some industry representatives were skeptical that the program would work on a practical level. Some worried that increased collaboration could have other side effects, such as reimbursement coverage decisions influencing whether or not a device makes it through the approval process.

"There’s an awful lot going on at FDA and CMS and I don’t think it would be in anyone’s best interest to tackle too much integration between the two entities at a time when they’re both going through substantial reform in their own right," president Stephen Ubl said at the time.

The parallel review program does not alter the different review standards for either agency, and is voluntary for companies eager to give it a try.

The pilot will last for up to two years with the potential for extension, and is primarily available for innovative technologies that can benefit from simultaneous review. It will only take 3 to 5 submissions per year.

Filed Under: Food & Drug Administration (FDA), Medicare, News Well Tagged With: 510(k) reforms, Centers for Medicare and Medicaid Services (CMS)

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy